Health And Wellness Weekly Trademarks Review: 5 September
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
You may also be interested in...
In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.
FDA Panel Will Have To Weigh Pediatric Cancer Drug’s ‘Higher Level’ Of Uncertainty Against Rare, Devastating Disease
US WorldMeds NDA package for eflornithine for high-risk neuroblastoma provides “a higher level of uncertainty than is typically seen in oncology applications,” agency says. Though FDA seems largely satisfied with the sponsor’s externally controlled study, confirmatory evidence may be lacking.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.